SYDNEY, March 5, 2026, 16:57 AEDT
- On March 4, CSL snapped up another 59,751 shares, bringing its cumulative buybacks up to 4.03 million shares.
- So far, the company has spent roughly A$739 million on its on-market buyback.
- CSL said 39,627 shares hit the market after employees exercised performance rights.
CSL Ltd accelerated its on-market share buyback this Wednesday, snapping up 59,751 shares for A$8.57 million, according to an exchange filing. So far, the company has bought back 4.03 million shares, spending close to A$739 million under the buyback plan, which is capped at US$750 million.
Persistent buying stands out, with CSL still working to calm investor nerves after its first-half earnings dropped and the company swapped leaders last month. Management is aiming for a stronger second half and stuck to its full-year guidance, while also bumping up its buyback.
The board faces mounting pressure for swift, decisive action. “Possibly a salvage mission,” was how David Tuckwell, chief investment officer at ETF Shares, described the move to appoint longtime company insider Gordon Naylor as interim chief executive. Reuters
CSL snapped up shares on Wednesday at prices ranging from A$142.43 to A$145.18 each, the filing showed. UBS Securities Australia is handling the buyback, set to continue through June 30.
CSL disclosed in a separate notice that 39,627 ordinary shares were issued or transferred on March 2 after conversion of employee “rights.” That tally includes 2,212 shares allocated to key management personnel Andrew Schmeltz. According to the filing, the shares were issued for nil consideration under CSL’s performance rights plan.
Performance rights give holders shares if certain targets are hit, potentially boosting the share count when exercised. According to the notice, CSL’s ordinary shares on issue stood at 485.15 million, with 2.61 million unquoted “rights” also on the books.
CSL ranks among Australia’s largest listed firms, producing vaccines, iron deficiency and kidney treatments, and plasma-based medicines. The key revenue driver: its plasma division, CSL Behring.
The buyback, though, won’t solve CSL’s operational hurdles. CSL itself has flagged that Seqirus earnings drop off in H2 — a direct result of the flu vaccine’s seasonality. Vifor faces margin pressure as generics move in. That puts Behring in the hot seat to deliver most of the recovery. Not much room for slip-ups, as Citi put it.
The next date in focus for CSL is its interim dividend schedule: shares go ex-dividend March 10, with the record date following on March 11, the company’s financial calendar shows.
